Summary & Overview
HCPCS G0681: HCT/P Non-Sheet Skin Substitute Application, First 25 sq cm
HCPCS Level II code G0681 denotes the application of a PMA-, 510(k)-, or 361-authorized human cells, tissues, or cellular and tissue-based product (HCT/P) in a non-sheet form used to treat wounds up to 100 square centimeters, specifically billing for the first 25 square centimeters or less. This code captures a growing class of advanced biologic wound therapies that can affect clinical pathways for complex or non-healing wounds and has implications for coverage, utilization management, and cost across payers nationally. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical application and coding scope of G0681, payer coverage context, and what to expect in benchmarking and policy considerations related to advanced skin substitutes. The summary outlines where G0681 is typically used, how it is reported for partial wound areas, and the role of PMA/510(k)/361 regulatory pathways in framing clinical adoption. Data not available in the input is noted where payer-specific rates, modifier usage, taxonomies, ICD-10 mappings, and related codes would normally appear.
Billing Code Overview
HCPCS Level II code G0681 describes the application of a premarket approval (PMA), 510(k), or 361 human cells, tissues, or cellular and tissue-based product (HCT/P) non-sheet form skin substitute for treatment of a wound surface area up to 100 square centimeters. The code is limited to the first 25 square centimeters or less of wound surface area treated.
-
Service type: Application of an HCT/P non-sheet form skin substitute to a wound
-
Typical site of service: Outpatient wound care clinic, hospital outpatient department, or other ambulatory care settings where advanced biologic wound therapies are applied
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a full-thickness or partial-thickness chronic wound (for example, a non-healing diabetic foot ulcer or a pressure ulcer) with a wound surface area up to 100 sq cm. The treating clinician (often a wound care specialist, podiatrist, or general surgeon) evaluates the wound in clinic, confirms failure of conservative measures (offloading, debridement, dressings, infection control, glycemic control) and documents wound dimensions and depth. The clinical workflow includes wound assessment and cleansing, sharp or enzymatic debridement as indicated, hemostasis, and measurement of the wound surface area. If the decision is made to apply a non-sheet skin substitute that is a premarket approval (PMA), 510(k) or 361 human cells, tissues, or cellular and tissue-based product (HCT/P) in non-sheet form, the provider orders the product, prepares the wound bed, applies the product covering up to the first 25 sq cm or less (billable under G0681), secures the graft with appropriate dressings, and documents product name, lot number, area treated, and post-application care. Follow-up visits monitor graft incorporation, signs of infection, and wound healing progress.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the application requires substantially greater work than typical for G0681 (extensive preparation, atypical difficulty) and documentation supports increased work. |